Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Neurosci Lett ; 651: 182-187, 2017 06 09.
Artigo em Inglês | MEDLINE | ID: mdl-28432028

RESUMO

This study investigates Se-phenyl-thiazolidine-4-carboselenoate (Se-PTC) protective activity against oxidative and behavioral stress in the model of mania induced by ouabain (OUA) in male rats. The compound used was Se-PTC (50mg/kg) and the positive control LiCl (45mg/kg) was administered for intragastric route (i.g.) 30min prior to administration of OUA (10-5M). OUA was dissolved in artificial cerebrospinal fluid (aCSF) and administered at the 5µl through an intracerebroventricular (i.c.v) cannula. The pretreatment with Se-PTC was effective in preventing the increase in locomotor activity induced by OUA, however the positive control LiCl is capable to block crossing augmentation induced by OUA. Na+/K+-ATPase activity was significantly reduced in OUA group and the Se-PTC to normalize Na+/K+-ATPase activity. Pretreatment with Se-PTC protect against the increase in catalase activity and thiobarbituric acid reactive species (TBARS) content in the brain caused by OUA. Therefore, Se-PTC is effective against OUA-induced hyperactivity and alterations in brain oxidative status of rats.


Assuntos
Comportamento Animal/efeitos dos fármacos , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/metabolismo , Encéfalo/efeitos dos fármacos , Fármacos Neuroprotetores/administração & dosagem , Compostos Organosselênicos/administração & dosagem , Estresse Oxidativo/efeitos dos fármacos , Tiazolidinas/administração & dosagem , Animais , Transtorno Bipolar/induzido quimicamente , Encéfalo/metabolismo , Modelos Animais de Doenças , Locomoção/efeitos dos fármacos , Masculino , Ouabaína/administração & dosagem , Ratos Wistar
2.
Biomed Res Int ; 2014: 316082, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24895565

RESUMO

Antibiotic resistance is considered one of the world's major public health concerns. The main cause of bacterial resistance is the improper and repeated use of antibiotics. To alleviate this problem, new chemical substances against microorganisms are being synthesized and tested. Thiazolidines are compounds having many pharmacological activities including antimicrobial activities. For this purpose some thiazolidine derivatives substituted at position 5 in the thiazolidine nucleus were synthesized and tested against several microorganisms. Using a disc diffusion method, antimicrobial activity was verified against Gram-positive, Gram-negative, and alcohol acid resistant bacteria and yeast. The minimum inhibition concentrations (MIC) and minimum bactericidal concentrations (MBC) were determined. All derivatives showed antimicrobial activity mainly against Gram-positive bacteria, with MIC values ranging from 2 to 16 µg/mL.


Assuntos
Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/síntese química , Fenômenos Fisiológicos Bacterianos/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Tiazolidinas/administração & dosagem , Tiazolidinas/síntese química , Relação Dose-Resposta a Droga , Dose Letal Mediana
3.
J Pharm Pharmacol ; 61(3): 339-45, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19222906

RESUMO

OBJECTIVES: Novel 5-benzilidene thiazolidinones have been synthesized and exhibited anti-inflammatory activity. In this work one of the compounds of the thiazolidinone chemical series, (5Z,E)-3-[2-(4-chlorophenyl)-2-oxoethyl]-5-(1H-indol-3-ylmethylene)-thiazolidine-2,4-dione (PG15) was investigated aiming to determine the drug's anti-inflammatory potential in pre-clinical studies. METHODS: Methods used included the in-vitro inhibition of cyclooxygenase-1 and -2, in-vivo evaluation of anti-inflammatory activity by air pouch and peritonitis models and the pharmacokinetic profile after intravenous (3 mg/kg) and oral (3 and 6 mg/kg) dosing to rats. KEY FINDINGS: A two-compartment model with a fast distribution and an elimination half-life of 5.9 +/- 3.8 h described the PG15 plasma profile after intravenous dosing. PG15 showed an erratic and rapid absorption following oral administration with peak concentrations between 0.5 and 1 h. PG15 0.1 microM inhibited more than 30% and 13% of purified cyclooxygenase-1 and -2 activity in vitro, respectively. A lack of dose dependency was observed for the anti-inflammatory effect in the dose range investigated (0.8-50 mg/kg), with a maximum of 67.2 +/- 4.6% inhibition of leucocyte migration in the carrageenan-induced air pouch model obtained with the 3 mg/kg dose, similar to that observed for indometacin 10 mg/kg. CONCLUSIONS: The erratic absorption of PG15 observed after oral dosing could explain the lack of anti-inflammatory dose dependency.


Assuntos
Anti-Inflamatórios/farmacologia , Indóis/farmacologia , Inflamação/tratamento farmacológico , Tiazolidinas/farmacologia , Administração Oral , Animais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/farmacocinética , Ciclo-Oxigenase 1/efeitos dos fármacos , Ciclo-Oxigenase 2/efeitos dos fármacos , Inibidores de Ciclo-Oxigenase/administração & dosagem , Inibidores de Ciclo-Oxigenase/farmacocinética , Inibidores de Ciclo-Oxigenase/farmacologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Meia-Vida , Indóis/administração & dosagem , Indóis/farmacocinética , Indometacina/farmacologia , Inflamação/fisiopatologia , Injeções Intravenosas , Leucócitos/efeitos dos fármacos , Leucócitos/metabolismo , Masculino , Camundongos , Peritonite/tratamento farmacológico , Peritonite/fisiopatologia , Ratos , Ratos Wistar , Tiazolidinas/administração & dosagem , Tiazolidinas/farmacocinética , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA